459 related articles for article (PubMed ID: 33162769)
1. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
.
Di Marzo V
Dialogues Clin Neurosci; 2020 Sep; 22(3):259-269. PubMed ID: 33162769
[TBL] [Abstract][Full Text] [Related]
2. Role of the Endocannabinoidome in Human and Mouse Atherosclerosis.
Piscitelli F; Silvestri C
Curr Pharm Des; 2019; 25(29):3147-3164. PubMed ID: 31448709
[TBL] [Abstract][Full Text] [Related]
3. Endocannabinoid system dysfunction in mood and related disorders.
Ashton CH; Moore PB
Acta Psychiatr Scand; 2011 Oct; 124(4):250-61. PubMed ID: 21916860
[TBL] [Abstract][Full Text] [Related]
4. Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome.
Di Marzo V; Silvestri C
Nutrients; 2019 Aug; 11(8):. PubMed ID: 31434293
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of the endocannabinoidome-gut microbiome axis in eating disorders.
Mir HD; Giorgini G; Di Marzo V
Psychoneuroendocrinology; 2023 Aug; 154():106295. PubMed ID: 37229916
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
Cristino L; Bisogno T; Di Marzo V
Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
[TBL] [Abstract][Full Text] [Related]
7. Neurobiological Processes Induced by Aerobic Exercise through the Endocannabinoidome.
Forteza F; Giorgini G; Raymond F
Cells; 2021 Apr; 10(4):. PubMed ID: 33920695
[TBL] [Abstract][Full Text] [Related]
8. Alterations of brain endocannabinoidome signaling in germ-free mice.
Manca C; Shen M; Boubertakh B; Martin C; Flamand N; Silvestri C; Di Marzo V
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158786. PubMed ID: 32795503
[TBL] [Abstract][Full Text] [Related]
9. Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling.
Manca C; Boubertakh B; Leblanc N; Deschênes T; Lacroix S; Martin C; Houde A; Veilleux A; Flamand N; Muccioli GG; Raymond F; Cani PD; Di Marzo V; Silvestri C
J Lipid Res; 2020 Jan; 61(1):70-85. PubMed ID: 31690638
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanism and Cannabinoid Pharmacology.
Schurman LD; Lu D; Kendall DA; Howlett AC; Lichtman AH
Handb Exp Pharmacol; 2020; 258():323-353. PubMed ID: 32236882
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoids and the Microbiota-Gut-Brain Axis: Emerging Effects of Cannabidiol and Potential Applications to Alcohol Use Disorders.
Karoly HC; Mueller RL; Bidwell LC; Hutchison KE
Alcohol Clin Exp Res; 2020 Feb; 44(2):340-353. PubMed ID: 31803950
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
Di Marzo V; Piscitelli F; Mechoulam R
Handb Exp Pharmacol; 2011; (203):75-104. PubMed ID: 21484568
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoid system and mood disorders: priming a target for new therapies.
Micale V; Di Marzo V; Sulcova A; Wotjak CT; Drago F
Pharmacol Ther; 2013 Apr; 138(1):18-37. PubMed ID: 23261685
[TBL] [Abstract][Full Text] [Related]
14. Cannabis and Neuropsychiatric Disorders: An Updated Review.
Chayasirisobhon S
Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
[TBL] [Abstract][Full Text] [Related]
15. The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders.
Ferber SG; Namdar D; Hen-Shoval D; Eger G; Koltai H; Shoval G; Shbiro L; Weller A
Curr Neuropharmacol; 2020; 18(2):87-96. PubMed ID: 31481004
[TBL] [Abstract][Full Text] [Related]
16. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R; Ambwani SR; Singh S
Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
[TBL] [Abstract][Full Text] [Related]
18. Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice.
Lacroix S; Pechereau F; Leblanc N; Boubertakh B; Houde A; Martin C; Flamand N; Silvestri C; Raymond F; Di Marzo V; Veilleux A
mSystems; 2019 Dec; 4(6):. PubMed ID: 31848310
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology of cannabinoids.
Grotenhermen F
Neuro Endocrinol Lett; 2004; 25(1-2):14-23. PubMed ID: 15159677
[TBL] [Abstract][Full Text] [Related]
20. (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders.
Sihag J; Di Marzo V
Lipids Health Dis; 2022 Jan; 21(1):9. PubMed ID: 35027074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
